Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

The holistic trial: A comprehensive evaluation of two second-line therapeutic approaches for immune thrombocytopenia (ITP) – a pragmatic randomized controlled trial

View Full Paper
Ask AI
Bookmark
Share

Authors

IOInge Christoffer OlsenHTHoa TranDDDoaa El Demerdash

Discussion

Loading...

Member takes

Overview

Randomized controlled trial compares rituximab and TPO-RAs for improving health related quality of life in ITP patients.

Key Points

  • To compare the effectiveness of second-line therapies for immune thrombocytopenia and assess patient-reported outcomes.
  • Open-label multicenter randomized controlled trial
  • Patients with persistent ITP despite corticosteroids
  • Primary endpoint: durable response rate (platelet count >50x10⁹/L)
  • Trial scheduled to begin in August 2025
  • Aim to randomize 220 participants from Norway, Sweden, Egypt, and Oman
  • Focus on treatment failure and health related quality of life evaluations.

Cite This Study

Olsen et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e320https://doi.org/10.1182/blood-2025-8226
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparative effectiveness of second-line therapies for chronic immune thrombocytopenia: A network meta-analysis of RCTs2025
  2. 2The prolong trial: A two Phase randomized placebo-controlled trial to optimize rituximab response with dexamethasone and maintenance therapy with low dose rituximab in immune thrombocytopenia (ITP) patients2025
  3. 3Rituximab beats the odds in ITP? a 5-year national showdown against TPO-ras2025
  4. 4Efficacy and safety of avatrombopag treatment in immune thrombocytopenia patients in Poland: a multicenter study2026
  5. 5Outcomes of rituximab as treatment for immune thrombocytopenic purpura in patients who have failed steroids or IVIG: A retrospective study in a community practice.2024